The emergence of immunotherapy is opening up treatment options for an increasing number of previously incurable diseases. Unfortunately, despite the growing popularity of immunotherapy, those who respond to the treatment remain in the minority. Finding new ways to identify and stratify patients who are the most likely to respond to specific immunotherapeutic approaches, therefore, is now a primary focus in the field.
Understanding a patient’s immunogenic responses can offer essential insights needed to guide immunotherapeutic treatment decisions. Advances in the imaging arena, such as the real-time, noninvasive visualization of specific cells, or the application of artificial intelligence (AI) in pathology, have garnered recent attention in the immunotherapy space. For instance, an artificial intelligence algorithm can detect previously unseen changes in CT scans patterns and determine how well patients with lung cancer would benefit from immunotherapy.
Additionally, while cell therapies hold great promise clinically, high manufacturing costs relative to reimbursement present a formidable roadblock to commercialization. The need for process efficiency, product consistency, and cost-effectiveness is driving automation efforts in numerous cell therapy fields, particularly for T-cell immunotherapies. To that end, a single-cell proteomics system can be used together to advance the future of T-cell immunotherapy. Each is a closed, fully automated bench top system that does not require numerous personnel and extensive training to run. Together, these next-generation platforms pave the way for decentralized manufacturing of novel cell therapies and a solution for complete functional characterization of each cell in a cell therapy product, to ensure correlative functional potency of the manufactured cell product.
At this juncture, there is a wide variety of immunotherapy companies entering the industry with a set of advanced and integrated immunotherapy solutions and service offerings. To help companies navigate through the best-of-breed immunotherapy companies, Pharma Tech Outlook has compiled a list of the top 10 immunotherapy companies. The enlisted organizations are transforming immunotherapy processes and treatments at the intersection of various disruptive technologies. Besides, the magazine also comprises insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for the aspiring CIOs and CXOs.
We present to you Pharma Tech Outlook’s, “Top 10 Immunotherapy Companies – 2020.”